REPLIGEN CORP

Repligen Corporation is a specialised life‑sciences company that supplies consumables, materials and systems used in the manufacturing of biologic medicines such as monoclonal antibodies. Its product mix includes chromatography resins (notably Protein A), filtration systems and process‑intensification technologies that often generate recurring revenue from repeat purchases. The business benefits from long development cycles and close relationships with large biopharma customers, offering potentially resilient margins, but growth is tied to demand for biologics and capital spending in biomanufacturing. At a market capitalisation of about $8.8bn, Repligen can be seen as a mid/large‑cap service provider to the booming biologics industry. Key considerations for investors include product concentration, supply‑chain execution, competition and the potential for acquisitions to add scale. This is general educational information, not personal advice — values can fall as well as rise and suitability depends on your circumstances.